Federal Register / Vol. 89, No. 43 / Monday, March 4, 2024 / Notices 15599 

from Type 1 Diabetes Clinical Studies (R01— 

Clinical Trial Not Allowed). 

Date: March 29, 2024. 

Time: 10:30 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

NIDDK, Democracy II, Suite 7000A, 6707 

Democracy Boulevard, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Ann A. Jerkins, Ph.D., 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 7119, 6707 Democracy Boulevard, 

Bethesda, MD 20892–2542, 301–594–2242, 

jerkinsa@niddk.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: February 27, 2024. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–04444 Filed 3–1–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The invention listed below is 

owned by an agency of the U.S. 

Government and is available for 

licensing to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Brian Bailey, Ph.D., at 240–669–5128 or 

301–201–9217, or by email at bbailey@

mail.nih.gov. Licensing information 

may be obtained by communicating 

with the Technology Transfer and 

Intellectual Property Office, National 

Institute of Allergy and Infectious 

Diseases, 5601 Fishers Lane, Rockville, 

MD 20852: tel. 301–496–2644. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of 

unpublished information related to the 

invention. 

SUPPLEMENTARY INFORMATION: 

Technology description follows: 

SARS–CoV–2 Pseudotyping Plasmids 

for Cutting-Edge Studies 

Description of Technology 

NIAID scientists have developed 

plasmids that allow for production of 

pseudoviruses expressing SARS–CoV–2 

spike protein. As SARS–CoV–2 is a 

lethal airborne virus, it must be handled 

in high-containment Biosafety Level 3 

(BSL–3) laboratories that require strict 

airflow, ventilation and 

decontamination procedures. The 

pseudotyping plasmids of this invention 

provide a secure platform for exploring 

SARS–CoV–2 dynamics without the 

need for high-risk handling of live virus 

and ensure a controlled environment for 

scientists to study SARS–CoV–2 more 

expeditiously in standard Biosafety 

Level 2 (BSL–2) laboratories. The 

plasmids can be used for diverse SARS– 

CoV–2 research applications, including 

the study of newly emerging or potential 

future variants of interest. 

This technology is available for 

licensing for commercial development 

in accordance with 35 U.S.C. 209 and 37 

CFR part 404, as well as for further 

development and evaluation under a 

research collaboration. 

Potential Commercial Applications 

• Research material that can be used 

in the development of neutralization 

assays 

Competitive Advantages 

• Expedite SARS–CoV–2 related 

experiments by enabling them to be 

conducted in laboratories with a lower 

Biosafety Level (BSL–2) than that 

required for handling SARS–CoV–2 

(BSL–3) 

Development Stage 

• Research material. 

Inventors 

Dr. Barney Graham, Dr. Lingshu 

Wang, Dr. John Mascola, Dr. Kizzmekia 

Corbett, all of NIAID. 

Intellectual Property 

HHS Reference No. E–223–2020–0. 

Licensing Contact 

To license this technology, please 

contact Brian Bailey, Ph.D.; 240–669– 

5128 or 301–201–9217; bbailey@

mail.nih.gov, and reference E–223– 

2020. 

Dated: February 14, 2024. 

Surekha Vathyam, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2024–04425 Filed 3–1–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The invention listed below is 

owned by an agency of the U.S. 

Government and is available for 

licensing to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Brian Bailey, Ph.D., at 240–669–5128 or 

301–201–9217, or by email at bbailey@

mail.nih.gov. Licensing information 

may be obtained by communicating 

with the Technology Transfer and 

Intellectual Property Office, National 

Institute of Allergy and Infectious 

Diseases, 5601 Fishers Lane, Rockville, 

MD 20852: tel. 301–496–2644. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of 

unpublished information related to the 

invention. 

SUPPLEMENTARY INFORMATION: 

Technology description follows: 

SARS–CoV–2 Spike Fused to Hepatitis 

B Surface Antigen 

Description of Technology: 

The emergence of the SARS–CoV–2 

virus and its immune-escaping variants 

have led to global COVID–19 pandemic/ 

endemic, underscoring the urgent need 

for effective vaccines with strong and 

durable immune responses. 

Researchers at the Vaccine Research 

Center (VRC) of the National Institute of 

Allergy and Infectious Diseases (NIAID) 

used a novel approach to SARS–CoV–2 

vaccine development by leveraging 

hepatitis B surface antigen (HBsAg), 

which has a proven track record of 

safety and efficacy in hepatitis B 

vaccines. They designed fusion protein 

constructs comprised of HBsAg linked 

by a series of glycine-serine residues to 

the prefusion stabilized spike protein of 

SARS–CoV–2. These constructs can selfassemble into nanoparticles in 

mammalian cells and bind monoclonal 

antibodies (mAbs) that are specific to 

different domains of the SARS–CoV–2 

spike. The nanoparticles elicit potent 

and durable immune responses 

including neutralizing antibody 


khammond on DSKJM1Z7X2PROD with NOTICES
15600 Federal Register / Vol. 89, No. 43 / Monday, March 4, 2024 / Notices 

response. In vitro and in vivo 

experiments demonstrate that this 

nanoparticle platform has the potential 

for use as a robust SARS–CoV–2 

vaccine. 

This technology is available for 

licensing for commercial development 

in accordance with 35 U.S.C. 209 and 37 

CFR part 404, as well as for further 

development and evaluation under a 

research collaboration. 

Potential Commercial Applications: 

• Novel SARS–CoV–2 vaccine and 

universal vaccines against coronavirus 

• Vaccine development against other 

viral pathogens such as HIV and flu 

Competitive Advantages: 

• Higher potency, potentially longer 

protection compared to other SARS– 

CoV–2 vaccine formulations. 

• Potent immune response via genetic 

delivery, including DNA and RNA 

immunization. 

• Improved immunogenicity 

compared to other nanoparticle or viruslike-particle (VLP)-based vaccines for 

SARS–CoV–2 spike protein. 

Development Stage: 

• Pre-Clinical. 

Inventors: Drs. John Mascola, Cuiping 

Liu, Wei Shi, Amarendra Pegu, Lingshu 

Wang, Wing-Pui Kong, all of NIAID. 

Publication: Liu, C., Wang, L., 

Merriam, J.S. et al. Self-assembling 

SARS–CoV–2 spike-HBsAg 

nanoparticles elicit potent and durable 

neutralizing antibody responses via 

genetic delivery. npj Vaccines 8, 111 

(2023). https://doi.org/10.1038/s41541- 

023-00707-w. 

Intellectual Property: HHS Reference 

No. E–171–2021–0–EIR–00 U.S. Patent 

Application No. 63/278,956 filed on 

November 12, 2021; HHS Reference No. 

E–171–2021–0–EIR–00 U.S. Patent 

Application No WO 2023/086961; PCT/ 

US2022/079750, filed on November 11, 

2022. 

Licensing Contact: To license this 

technology, please contact Brian Bailey, 

Ph.D.; 240–669–5128 or 301–201–9217; 

bbailey@mail.nih.gov, and reference E– 

171–2021. 

Collaborative Research Opportunity: 

The National Institute of Allergy and 

Infectious Diseases is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize this technology. Areas of 

specific interest include (a) testing 

developability of the antibodies elicited 

by SARS–CoV–2 spike-HBsAg 

nanoparticles (e.g., biophysical 

characteristics, cross-reactivity, 

pharmacokinetics, toxicity), (b) preclinical model assessment, and (c) 

human clinical trials. For collaboration 

opportunities, please contact Brian 

Bailey, Ph.D.; 240–669–5128 or 301– 

201–9217, bbailey@mail.nih.gov. 

Dated: February 15, 2024. 

Surekha Vathyam, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2024–04423 Filed 3–1–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Fellowships: Physiology and Pathobiology of 

Cardiovascular and Respiratory Systems: 

Cardiovascular. 

Date: March 21–22, 2024. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Michael L. Bloom, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6187, 

MSC 7804, Bethesda, MD 20892, 301–451– 

0132, bloomm2@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Topics in Microbial and Host 

Interactions. 

Date: March 21, 2024. 

Time: 10:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Jui Pandhare, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 594–7735, pandharej2@

csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Atherosclerosis and Vascular Inflammation. 

Date: March 21, 2024. 

Time: 11:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Natalia Komissarova, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5207, 

MSC 7846, Bethesda, MD 20892, 301–435– 

1206, komissar@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Population and Public Health 

Approaches in HIV/AIDS. 

Date: March 22, 2024. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Elia E. Ortenberg, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3108, 

Bethesda, MD 20892, 301–827–7189, 

femiaee@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Molecular Genetics and Genomics. 

Date: March 22, 2024. 

Time: 1:00 p.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Brian Paul Chadwick, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 594–3586, chadwickbp@

csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Cell, Structure and Function-1. 

Date: March 22, 2024. 

Time: 1:00 p.m. to 6:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Anne Marie Strohecker, 

Ph.D., Center for Scientific Review, National 

Institutes of Health, 6701 Rockledge Drive, 

Bethesda, MD 20892, (301) 867–5309, 

stroheckeram@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; RFA–RM– 

23–013: Partnerships with Common Fund 

Data Ecosystem Resources. 

Date: March 26, 2024. 

Time: 9:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 


khammond on DSKJM1Z7X2PROD with NOTICES